Eloxx Pharmaceuticals, Inc. financial data

Location
Arlington, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 17 Mar 2026

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5,071,935 shares
Common Stock, Shares, Outstanding 4,790,239 shares 36%
Entity Public Float $330,000 USD
Common Stock, Value, Issued $48,000 USD 37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,785,000 USD 4211%
Assets, Current $5,270,000 USD 77%
Property, Plant and Equipment, Net $0 USD
Operating Lease, Right-of-Use Asset $0 USD
Assets $5,270,000 USD 77%
Accounts Payable, Current $2,713,000 USD -49%
Employee-related Liabilities, Current $698,000 USD 46%
Accrued Liabilities, Current $1,613,000 USD 12%
Liabilities, Current $17,177,000 USD -37%
Operating Lease, Liability, Noncurrent $0 USD
Liabilities $17,177,000 USD -37%
Retained Earnings (Accumulated Deficit) $300,580,000 USD -2%
Stockholders' Equity Attributable to Parent $11,907,000 USD 51%
Liabilities and Equity $5,270,000 USD 77%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 4,790,239 shares 36%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Deferred Tax Assets, Valuation Allowance $94,644,000 USD 0.83%
Deferred Tax Assets, Gross $94,644,000 USD 0.83%
Property, Plant and Equipment, Gross $0 USD
Operating Lease, Liability, Current $0 USD -100%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -100%
Deferred Tax Assets, Operating Loss Carryforwards $73,691,000 USD 4.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%